Evidence map›Paper›PMID 23379618›Full record

ReviewACS chemical neuroscience2013

Noninvasive and targeted drug delivery to the brain using focused ultrasound.

Alison Burgess, Kullervo Hynynen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS chemical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 141 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Sonodynamic biomimetic-nanomedicine fight cancers.Journal of nanobiotechnology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Alison BurgessPhysical Sciences, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Kullervo Hynynen
Sunnybrook Health Science Centre · CASunnybrook Research Institute

Funding

Ultrasound Therapy Delivery Through Intact SkullR01EB003268 · NIBIB · SUNNYBROOK & WOMEN'S COLL HLTH SCIS CTR · PI HYNYNEN, KULLERVO · 2003 to 2020
$8.2M
Canadian Institutes of Health Research FRN 119312NIBIB NIH HHS R01 EB003268
6 · The paper itself

Abstract

Brain diseases are notoriously difficult to treat due to the presence of the blood-brain barrier (BBB). Here, we review the development of focused ultrasound (FUS) as a noninvasive method for BBB disruption, aiding in drug delivery to the brain. FUS can be applied through the skull to a targeted region in the brain. When combined with microbubbles, FUS causes localized and reversible disruption of the BBB. The cellular mechanisms of BBB disruption are presented. Several therapeutic agents have been delivered to the brain resulting in significant improvements in pathology in models of glioblastoma and Alzheimer's disease. The requirements for clinical translation of FUS will be discussed.

Indexed as

AnimalsBlood-Brain BarrierBrainDrug Delivery SystemsHigh-Energy Shock WavesHumansPharmaceutical PreparationsUltrasonic TherapyPharmaceutical Preparations

Identifiers

PMID23379618
PMCPMC3629738
OpenAlexW2015112725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.